Literature DB >> 307552

Primary structure of human alpha1-protease inhibitor. The complete amino acid sequence of cyanogen bromide fragment II.

D Shochat, S Staples, K Hargrove, J S Kozel, S K Chan.   

Abstract

The complete amino acid sequence of a CNBr-fragment from human alpha1-protease inhibitor has been determined and is shown below. The peptide consists of 109 amino acid residues with 1 oligosaccharide unit. The 2 glutamic acid residues which have previously been shown to be substituted by lysine in the Z and by valine in the S mutant proteins are both located in this CNBr fragment. (formula: see text).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 307552

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  The identification of epitopic sites in human alpha 1-proteinase inhibitor.

Authors:  X J Zhu; S S Kang; K Hargrove; D Shochat; M Jarrells; M Mojesky; S K Chan
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

2.  The use of monoclonal antibodies to distinguish several chemically modified forms of human alpha 1-proteinase inhibitor.

Authors:  X J Zhu; S K Chan
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

3.  Cloning and sequence of cDNA coding for alpha 1-antitrypsin.

Authors:  K Kurachi; T Chandra; S J Degen; T T White; T L Marchioro; S L Woo; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

4.  Chemical modification of human alpha 1-proteinase inhibitor by tetranitromethane. Structure-function relationship.

Authors:  S Mierzwa; S K Chan
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

5.  A defect in the structure of type I procollagen in a patient who had osteogenesis imperfecta: excess mannose in the COOH-terminal propeptide.

Authors:  L Peltonen; A Palotie; D J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.